What Your Heart Knows: The Cardiovascular Cost of Untreated Sleep Apnea

Why the connection matters now

Sleep apnea has been clinically recognized for decades, but the depth of its connection to cardiovascular disease is a more recent understanding. The clinical literature accumulating since the early 2000s has documented that obstructive sleep apnea is independently associated with — and frequently a contributor to — hypertension, atrial fibrillation, coronary artery disease, heart failure, stroke, and sudden cardiac death.

The American Heart Association now publishes scientific statements on sleep apnea screening in cardiovascular patients. The European Society of Cardiology has integrated sleep-disordered breathing screening into its atrial fibrillation guidelines. Cardiology fellowships increasingly include sleep medicine rotations. The shift, in summary, is that OSA is no longer treated as a separate condition that happens to coexist with heart disease — it is treated as a modifiable cardiovascular risk factor.

What happens to the heart during apnea events

The cardiovascular damage of obstructive sleep apnea is not produced by any single event. It is produced by the cumulative effect of hundreds of nightly breathing interruptions, repeated over years, each one of which provokes a stereotyped cardiovascular response.

During an apnea event — the airway closes, breathing stops, oxygen drops — three things happen simultaneously to the cardiovascular system:

• Sympathetic nervous system activation — the brain detects falling oxygen and triggers a stress response. Heart rate rises, blood vessels constrict, and blood pressure surges. This response is appropriate in a true emergency; repeated several hundred times a night for years, it produces chronic sympathetic overactivation that persists into the daytime.
• Intrathoracic pressure swings — when the patient strains to breathe against a closed airway, the pressure inside the chest plummets and then rebounds with each apnea cycle. These mechanical swings produce direct stress on the heart muscle, the great vessels, and particularly the left atrium — which is one mechanism through which atrial fibrillation develops.
• Oxidative stress and endothelial dysfunction — the repeated oxygen desaturations and re-oxygenations produce cellular-level damage to the lining of blood vessels, accelerating the development of atherosclerosis, the underlying process behind coronary artery disease and stroke.

Daytime blood pressure stays higher than it should. Nighttime blood pressure — which in healthy people drops by 10 to 20% during sleep — stays flat or rises (a pattern called "non-dipping" that is itself a cardiovascular risk factor). Heart rate variability is reduced. The arrhythmia substrate gradually develops. Years pass. The cumulative damage is silent and progressive.

The cardiovascular conditions OSA contributes to

The clinical associations are now well-established and span much of cardiovascular medicine.

Hypertension

Untreated OSA contributes to development and worsening of high blood pressure. The connection is strongest in treatment-resistant hypertension — defined as blood pressure not adequately controlled by three or more medications — where the prevalence of OSA approaches 80%. CPAP therapy in patients with both conditions typically lowers blood pressure by a clinically meaningful amount, often where additional medication adjustments have not.

Atrial fibrillation

Approximately half of patients with atrial fibrillation have obstructive sleep apnea, and the majority of those are undiagnosed at the time of their AF diagnosis. Untreated OSA is associated with substantially higher rates of AF recurrence after both pharmacologic and electrical cardioversion, and after catheter ablation. Treating the OSA before or alongside rhythm-control treatment improves the durability of the AF treatment.

Heart failure

OSA is present in roughly 30 to 50% of patients with heart failure across the spectrum of ejection fractions, often unrecognized. Untreated OSA worsens heart failure outcomes; treating it with CPAP improves cardiac function, exercise capacity, and quality of life in many patients. A related but distinct pattern — central sleep apnea, including Cheyne-Stokes respiration — is particularly common in advanced heart failure and requires specialized evaluation.

Coronary artery disease and stroke

Untreated OSA accelerates atherosclerosis through the oxidative stress and endothelial dysfunction described above. Patients with OSA have elevated rates of myocardial infarction and ischemic stroke compared with similar patients without OSA. The risk of stroke specifically is substantially elevated, and stroke during sleep hours — when OSA events are concentrated — is a recognized clinical pattern.

Sudden cardiac death

Untreated OSA is associated with increased risk of sudden cardiac death, with the elevation concentrated in the overnight hours when apnea events and the resulting cardiovascular stress responses are occurring. The pattern of overnight sudden cardiac death — in contrast with the morning peak typical of cardiovascular events generally — is partly a signature of underlying sleep-disordered breathing.

What treatment changes

The clinical question for any patient with cardiovascular disease and untreated OSA is whether treating the OSA changes the cardiovascular trajectory. The answer is increasingly: yes, and meaningfully.

• Blood pressure — CPAP in patients with both OSA and hypertension typically reduces 24-hour blood pressure in a clinically meaningful range, with larger effects in treatment-resistant hypertension and in patients with high adherence to therapy.
• Atrial fibrillation — treating OSA reduces AF recurrence after cardioversion and ablation, with the effect size large enough that contemporary AF guidelines specifically recommend OSA evaluation in AF patients with appropriate risk profiles.
• Heart failure — CPAP in heart failure patients with OSA improves left ventricular function, exercise tolerance, and quality of life; the evidence is strongest for heart failure with reduced ejection fraction.
• Cardiovascular events — the question of whether treating OSA reduces myocardial infarctions and strokes has been studied in randomized trials with mixed results, and is most likely to show benefit in patients with high-symptom burden, severe OSA, and good treatment adherence. The mechanistic case is strong; the trial evidence is real but heterogeneous.

The honest synthesis is that treating OSA in cardiovascular patients improves blood pressure, reduces AF recurrence, and improves heart failure outcomes; the broader question of whether it reduces hard cardiovascular events depends meaningfully on which patients are treated and how well they tolerate therapy. Adherence is central. Patients who use CPAP consistently get the cardiovascular benefit; patients who do not, do not.

Who should be screened

Sleep apnea screening makes the most clinical sense in cardiology populations where the prevalence is highest and the treatment effect is largest. The patient profiles that most often warrant evaluation:

• Treatment-resistant hypertension — blood pressure not controlled despite three or more antihypertensive medications
• Atrial fibrillation, particularly recurrent or persistent forms
• Heart failure across the ejection fraction spectrum
• Stroke or transient ischemic attack, particularly when occurring during sleep hours or in patients with known OSA risk factors
• Coronary artery disease with persistently elevated cardiovascular risk despite optimization
• Pulmonary hypertension
• Bradyarrhythmias and conduction abnormalities of unclear cause

If you carry one of these diagnoses and have any of the OSA-suggestive features — loud habitual snoring, witnessed breathing pauses, excessive daytime sleepiness, morning headaches, or refractory hypertension — the conversation worth having with your cardiologist or primary care physician is whether evaluation for obstructive sleep apnea belongs in the workup. For most patients, the next step is a home sleep apnea test, which is non-invasive and generally covered by insurance when clinically indicated.

The takeaway

Sleep apnea is a treatable medical condition with established cardiovascular consequences. For patients without heart disease, untreated OSA is a long-term cardiovascular risk factor. For patients with heart disease, it is frequently a present-tense contributor that, if treated, changes the trajectory of the underlying cardiovascular condition.

Cardiology is asking about sleep more often than it used to. The reason is that the evidence has crossed a threshold: enough patients have improved enough on appropriate sleep apnea treatment that the cardiovascular community treats screening as a real lever, not a side note. If you carry a cardiovascular diagnosis and your sleep has not been evaluated, that is a question worth raising — at the next visit, with the phrasing that gets it taken seriously: "Given my [diagnosis], should I be evaluated for obstructive sleep apnea?"

The body keeps score. The heart is one of the places where the bill comes due.